Rank #1: Gut Feeling: The Links Between IBD and Mental Health
Guest: Alison Kaufman, PsyD
Our body responds to stress and anxiety in a variety of ways. For patients with IBD, the body manifests stress into various psychological issues, creating a link between IBD and mental health.
Dr. Alison Kaufman, a psychologist at Children’s Hospital of Philadelphia will discuss the common emotional reactions of IBD patients, suggesting ways for physicians to help these patients cope with their chronic disease. She is joined by Dr. Adam Ehrlich of Temple University.
Rank #2: Diet Nutrition in the Management of IBD
Guest: James D. Lewis, MD, MSCE
Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges?
Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.
Rank #3: Biologics for Inflammatory Bowel Disease: Maximizing Benefits, Avoiding Complications
Guest: Gary Lichtenstein, MD
Recorded on location at the Crohn’s & Colitis Foundation’s Annual Meeting in Orlando, host Dr. Lea Ann Chen, Assistant Professor of Medicine at New York University, discusses potential complications of biologics with Dr. Gary Lichtenstein, Professor of Medicine at the Hospital of the University of Pennsylvania.
Rank #4: IBD Preventive Care: Clinical Priorities for Best Patient Outcomes
Guest: Adam Ehrlich, MD, MPH
Guest: John D. Betteridge, MD
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Brian McDonough leads an expert panel focusing on preventive care for IBD patients. Joining the expert panel are:
- Dr. Adam C. Ehrlich, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Co-Medical Director of the Temple Inflammatory Bowel Disease Program, and
- Dr. John D. Betteridge, Gastroenterologist at Lancaster General Hospital and Regional Gi Medical Center. Drs. Ehrlich and Betteridge discuss the issues surrounding IBD with a focus on preventative care in patients.
Discussion points include micronutrient deficiencies, immunosuppression, methods to maintain a well-balanced nutrient-rich diet, and communication strategies between PCPs and GI specialists to improve patient care.
Rank #5: Emerging 'Bowel-Sparing' Procedures for Crohn's Disease
Guest: Fabrizio Michelassi, MD
As a gastrointestinal surgeon and Chairman of Surgery at Weill Cornell, Dr. Fabrizio Michelassi has witnessed the possible complications that can stem from Crohn's disease. He joins Dr. Jennifer Caudle to provide his perspective on new surgical approaches to treat strictures and fibrostenotic complications.
Rank #6: The Latest Treatment Options for IBD Patients
Guest: Adam Ehrlich, MD, MPH
As new treatment options become available for IBD patients, it is important to be informed on which treatments will work best for which patient populations. Dr. Adam Ehrlich, Assistant Professor of Medicine at Temple University School of Medicine, joins Rebecca Kaplan to discuss what's coming down the drug pipeline for patients with IBD. He will touch on the recent medication approvals of biologics and biosimilars, as well as how IBD treatments are moving closer to precision medicine.
Rank #7: Crohn’s Colitis Congress: Nutritional Therapy for IBD: From Theory to Your Practice
Guest: James D. Lewis, MD, MSCE
After the “Nutritional Therapy for IBD: From Theory to Your Practice” session at the second annual Crohn’s & Colitis Congress in Las Vegas, dietician Kelly Issokson and Dr. James Lewis recap the key takeaways, how you can implement those takeaways into your practice, and the benefits of recruiting dieticians and other healthcare professionals to provide your IBD patients with nutritional therapy.
Rank #8: IBD: A Journey from Parent to Advocate
For many IBD patients and their parents, becoming involved with advocacy groups provides an excellent support system, especially since this can be a difficult disease to manage. But some also use these groups to make a difference not only locally, but also nationally.
Sharing his personal-turned-professional journey with Dr. Jennifer Caudle is Frank Russomano, President and CEO of ReachMD, who is also joined by the President & CEO of the Crohn’s & Colitis Foundation, Michael Osso.
Rank #9: Addressing the Psychosocial Impacts of IBD
Guest: Megan E. Riehl, PsyD
Psychosocial disorders like anxiety and depression can be especially severe when combined with the physical symptoms of IBD. Fortunately, there are ways gastroenterologists, primary care providers, and mental health specialists can all work together to address these effects as early as possible, as Dr. Megan Riehl, Clinical Assistant Professor of Medicine and Clinical Psychologist at the University of Michigan, explains.
Rank #10: Extraintestinal Findings in Inflammatory Bowel Disease
Guest: Christina Y. Ha, MD
Dr. Caren Heller, Chief Scientific Officer at the Crohn’s & Colitis Foundation chats with Dr. Christina Ha, Assistant Clinical Professor of Gastroenterology at the University of California-Los Angeles about what physicians need to know regarding extraintestinal findings in IBD.
Rank #11: Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.Liefferinckx C1, Minsart C, Toubeau JF, Cremer A, Amininejad L, Quertinmont E, Devière J, Gils A, van Gossum A, Franchimont D.
Infliximab (IFX) is indicated for the treatment of inflammatory bowel diseases (IBD). Nevertheless, loss of response (LOR) to IFX is reported in up to 10% to 30% of patients within the first year of treatment. Our objective was to evaluate the impact of the pharmacokinetics of IFX at induction on treatment failure.
This is a longitudinal cohort study on 269 patients with IBD treated with IFX in a single center. A total of 2331 blood samples were prospectively collected from 2007 until March 2015 with a retrospective analysis of clinical data. IFX trough levels (TLs) were measured by enzyme-linked immunosorbent assay. Antibodies to IFX were measured by drug-sensitive bridging assay.
During follow-up, patients were defined according to treatment outcome. At week 6, median IFX TL in patients requiring a switch to another treatment due to LOR (LOR switched group) (2.32 μg/mL [0.12-19.93 μg/mL]) was lower than in patients with long-term response (long-term responders) (8.66 μg/mL [0.12-12.09 μg/mL], P = ...
Rank #12: The Crohn’s Colitis Foundation's Camp Oasis: A Clinician's Perspective
Guest: Neilanjan Nandi, MD, FACP
Guest: Susan Peck, MSN, CRNP
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Philip Stein talks with Dr. Neilanjan Nandi and nurse practitioner Susan Peck about their respective experiences with The Crohn’s & Colitis Foundation's Camp Oasis. This camp gives children with IBD the opportunity to meet other kids with the same chronic illness, teaching them how to cope with their disease, manage their own medical needs, try new sports and activities, build confidence and independence, and most importantly, spend quality time just being a kid.
Rank #13: Anemia Care for IBD Patients
Guest: Jason Ken Hou, MD, MS, FACG
Patients with inflammatory bowel diseases (IBD) are at a greater risk of developing anemia, a common complication that affects their quality of life and is associated with high rates of other IBD-related complications.
Host Laura Wingate, Vice President of Education, Support and Advocacy for the Crohn's & Colitis Foundation, chats with Dr. Jason Hou, Assistant Professor of Gastroenterology at Baylor College of Medicine about gaps in the importance of anemia management, diagnostics, and awareness for patients with IBD that continue to exist among healthcare providers.
Rank #14: Iron Sequestration in Microbiota Biofilms in Treatment for IBD
Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.
Significant alterations of intestinal microbiota and anemia are hallmarks of inflammatory bowel disease (IBD). It is widely accepted that iron is a key nutrient for pathogenic bacteria, but little is known about its impact on microbiota associated with IBD. We used a model device to grow human mucosa-associated microbiota in its physiological anaerobic biofilm phenotype. Compared to microbiota from healthy donors, microbiota from IBD patients generate biofilms ex vivo that were larger in size and cell numbers, contained higher intracellular iron concentrations, and exhibited heightened virulence in a model of human intestinal epithelia in vitro and in the nematode Caenorhabditis elegans. We also describe an unexpected iron-scavenging property for an experimental hydrogen sulfide-releasing derivative of mesalamine. The findings demonstrate that this new drug reduces the virulence of IBD microbiota biofilms through ...
Rank #15: Travel for IBD Patients: How to Help Them Prepare
Guest: Adam Kaufman, MD
From the ReachMD studios in Fort Washington, Pennsylvania, host Dr. Adam C. Ehrlich talks with Dr. Adam Kaufman, Gastroenterologist at Main Line Gastroenterology Associates. Dr. Kaufman brings to the forefront the importance of preparing your IBD patient for travel. Discussion points include scheduling a pre-travel counsel visit, medication choices and proper storage procedures, vaccination considerations, blood clot prophylaxis, and travel insurance.
Rank #16: Improving Care for Children with IBD
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. Jose Fernando Del Rosario, head of Pediatric Gastroenterology at the Nemours Alfred I. duPont Hospital for Children in Wilmington, DE. Dr. Del Rosario and his department are the recipients of this year’s Gold Medallion Award from the Foundation. He discusses providing a positive experience for the patient and the importance of teaching children how to manage their health while living with a chronic condition, regaining quality of life and the most recent treatments for managing IBD, including nutritional therapy.
Rank #17: A Message from the President CEO of Crohn’s Colitis Foundation
Hear from Michael Osso, President and CEO of the Crohn’s & Colitis Foundation, as he talks about the Crohn’s & Colitis Foundation Perspectives series on ReachMD.
Rank #18: RISK Cohort Study in Crohn's Disease
From the 42nd Annual Renaissance Ball in Philadelphia benefiting the Crohn's & Colitis Foundation, host Lu Ann Cahn talks with Dr. David Piccoli, Chief of the Division of Gastroenterology, Hepatology and Nutrition, Director of the Biesecker PediatricLiver Center, and a board-certified pediatric gastroenterologist at Children's Hospital of Philadelphia. Dr. Piccoli discusses the RISK study, supported by the Crohn’s & Colitis Foundation, and the challenges patients face with response to treatment. This pediatric study enrolled 1,800 patients at the time of their diagnosis and collected clinical, genetic, treatment and microbiome information to help to determine how the immune system works over time.
Rank #19: Crohn’s Colitis Congress: How to Manage Complicated IBD
Guest: Judy Cho, MD
At the second annual Crohn’s & Colitis Congress in Las Vegas, Dr. Alesandro Fichera and Dr. Judy Cho discuss the session that they co-moderated about the management of complicated IBD and the breakthroughs for Crohn's disease management that could limit your patients’ need for surgery.
Rank #20: Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study
Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.Vavricka SR1, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N, Juillerat P, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Heinrich H, Manser CN, Safroneeva E, Raja Ali RA, Rogler G, Schoepfer AM, Greuter T; Swiss IBD Cohort Study Group.
Extraintestinal manifestations (EIMs) in patients with inflammatory bowel disease (IBD) are frequently observed. Little is known about the efficacy of anti-tumor necrosis factor (TNF) in EIM management. We assessed the effect of 3 anti-TNF agents (infliximab, adalimumab, and certolizumab pegol) on EIM evolution.
Data on 1249 patients from the Swiss IBD Cohort Study (SIBDCS) were analyzed. All EIMs were diagnosed by relevant specialists. Response was classified into improvement, stable disease, and clinical worsening based on the physician's interpretation.
Of the 366 patients with at least 1 EIM, 213 (58.2%) were ever treated with an anti-TNF. A total of 299 treatments were started for 355 EIMs. Patients with EIM were significantly more often treated with anti-TNF compared with those without EIM (58.2% versus 21.0%, P < 0.001). ...